The company Desitin Arzneimittel GmbH is active on international (Germany, Switzerland, Scandinavia, Eastern Europe) level. At our Hamburg plant we produce sophisticated products for the treatment of neurological and psychiatric illnesses and offer a large number of established and innovative products, especially for our core indications epilepsy and Parkinson’s syndrome.
of pharmacotherapy through continuous development and in cooperation with other
future-oriented companies, e.g. diseases of the central nervous system, is one
of Desitin’s main areas of activity and investment.
training and scientific information as well as cooperation with the treating
physicians and centres are our company’s further contribution to long-term
treatment success for neurological-psychiatric diseases.
ourselves as a partner for physicians, pharmacists and patients as well
as their families and provide extensive service as product support.
Our highly specialised field staff as well as our medical employees provide the
physicians with expert and competent assistance.
We also regard ourselves as advocates to patients suffering from epilepsy and Morbus Parkinson in order to protect them from negative effects on their diagnosis and treatment during changes in public health care. In this regard we seek and find dialogue with cost payers and health ministers in order to increase their understanding of the special requirements of these CNS illnesses.
Desitin is focused on pharmaceuticals for the treatment of epilepsy as well as Parkinson´s disease. It is the only manufacturer that offers the entire spectrum of products recommended by the WHO for the treatment of epilepsy.
Desitin not only offers a wide range of different therapeutics, but also a broad spectrum of presentations and dosage strengths.
Whereas most of these preparations have been developed inhouse by Desitin and successfully sold within various countries of Europe, co-operations with licensors and the successful marketing of products licenced represent a corner stone of Desitin’s latest developments.